- Home
- TVRD vs ATRA Comparison
TVRD vs ATRA Comparison
Compare TVRD & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TVRD | ATRA |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3M | 37.6M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | TVRD | ATRA |
|---|---|---|
| Price | $3.64 | $4.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $51.67 | $6.00 |
| AVG Volume (30 Days) | 51.6K | ★ 123.1K |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.93 |
| Revenue | N/A | ★ $128,940,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.43 |
| Revenue Growth | N/A | ★ 1404.02 |
| 52 Week Low | $3.50 | $4.13 |
| 52 Week High | $43.65 | $19.15 |
Technical Indicators
Market Signals| Indicator | TVRD | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.19 | 27.85 |
| Support Level | $3.51 | $4.13 |
| Resistance Level | $3.89 | $4.64 |
| Average True Range (ATR) | 0.29 | 0.30 |
| MACD | -0.00 | 0.30 |
| Stochastic Oscillator | 23.40 | 9.21 |
Price Performance
Historical ComparisonAbout TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).